Extraordinary Meeting of Q-Med AB (publ)

Extraordinary Meeting of Q-Med AB (publ) 

The Board of Directors of Q-Med AB (publ) has published a notice to attend the
Extraordinary General Meeting, which will be held on Wednesday February 4, 2009
at 3 p.m. on Q-Med's premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden.
A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in
Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of
the Extraordinary General Meeting in English can be found on the corporate web
site www.q-med.com and is also attached.

Q-Med AB (publ)

The Board

Queries should be addressed to: 
Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 (0) 70 974 9071


Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.